GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to deliver Lead Molecules
GVK Biosciences (GVK BIO) and CRELUX announced that they have set-up a highly robust fragment-based drug discovery platform proven to deliver rapidly, viable lead molecules. CRELUX’s high performance structural biology technologies together with GVK BIO’s mature computer-assisted drug design (CADD) tools and other components of its drug discovery & development engine, encompass all steps from challenging targets to novel drug candidates.
According to the companies, CRELUX and GVK BIO will provide seamless integration of all aspects of structure-based drug design for the Biopharmaceutical industry and furnishes accelerated timelines for moving molecules from concept into the clinic at an optimal cost. Fragment-based Drug Design (FBDD) helps in visualizing binding modes and hence rationalize an accelerated SAR allowing efficient lead optimization through CADD. CRELUX will leverage its capabilities of all aspects of multifaceted structural studies towards X-ray elucidation of fragment or lead target complexes, whereas GVK BIO will perform all discovery chemistry and biology work including in silico, in vitro and in vivo studies as well as activities necessary to ensure pre-clinical candidate nomination.
The biotech company 4SC AG announced that its drug discovery affiliate 4SC Discovery GmbH and CRELUX GmbH have entered into a strategic partnership for integrated drug discovery services. Both partners are adding core competencies to a joint discovery platform geared towards comprehensive d ... more
CRELUX and ProQinase announced that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures. Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grad ... more
CRELUX GmbH provides fast and affordable access to co-crystal structures for biotech and pharma companies worldwide. Three dimensional structures of target-compound complexes are unique sources of information during the rational drug discovery process. Straightforward availability of struct ... more
A number of medicines for which authorisation in the European Union (EU) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, says the European Medicines Agency (EMA). The recommendation is based on findings from an inspection that ra ... more
GVK Biosciences announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University. As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identi ... more
GVK Biosciences (GVK BIO) announced that it was awarded the Frost & Sullivan 2011 Best Practices Award for Growth Leadership in the Contract Research Services Market.
The Frost & Sullivan Award for Growth Leadership is presented to the company that has demonstrated excellence in capturing a ... more
GVK Biosciences, Asia’s leading Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. GVK BIO accelerates the Drug Discovery and Development process of its customers through science and innovation. GVK BIO has a diverse customer ... more